Literature DB >> 18086182

Increasing the uptake of hepatitis C virus testing among injecting drug users in specialist drug treatment and prison settings by using dried blood spots for diagnostic testing: a cluster randomized controlled trial.

M Hickman1, T McDonald, Ali Judd, T Nichols, V Hope, S Skidmore, J V Parry.   

Abstract

The objective of this study was to assess whether introducing dried blood spot testing can increase hepatitis C virus (HCV) diagnostic testing. A cluster randomized controlled trial was conducted. Sites were matched into pairs, with one site in each pair randomly allocated to receive the intervention (training and use of dried blood spot). Data were collected from all sites for 6 months before and 6 months after the start of the intervention. The participants were 22 specialist drug clinics and six prisons in England and Wales. The main outcome measure of this study was percentage point difference in individuals tested for HCV (the difference between the percentage of patients tested 6 months after and 6 months before the introduction of dried blood spot tests). Before the trial, 8% of patients at control and intervention sites had been tested for HCV, with 16 sites testing less than 5% of their caseload. The average percentage point difference between intervention and control sites was 14.5% (95% CI 1.3-28%, paired t-test, P = 0.03); with 13 of the 14 pairs contributing to the positive effect of the intervention (Wilcoxon matched-pairs signed-rank-test, P = 0.002). The size of the difference between intervention and control sites varied considerably. The study provides preliminary supporting evidence that dried blood spot testing may increase the uptake of HCV diagnostic testing, by increasing the opportunity for patients to be offered testing. Additional trials with a larger number of sites are justified, ideally in the context of drug and treatment policies that gave clearer priority (and targets) to infection control and testing.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18086182     DOI: 10.1111/j.1365-2893.2007.00937.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  30 in total

1.  Public health implications of rapid hepatitis C screening with an oral swab for community-based organizations serving high-risk populations.

Authors:  Ann Drobnik; Caroline Judd; David Banach; Joseph Egger; Kevin Konty; Eric Rude
Journal:  Am J Public Health       Date:  2011-09-22       Impact factor: 9.308

2.  Awareness of biologically confirmed HCV among a community residing sample of drug users in Baltimore City.

Authors:  Nicole Ennis Whitehead; Lauren E Hearn; Michael Marsiske; Maria R Kahn; William W Latimer
Journal:  J Community Health       Date:  2014-06

3.  Evaluation of dried blood spot as an alternative sample collection method for hepatitis C virus RNA quantitation and genotyping using a commercial system.

Authors:  Supriya Mahajan; Manish Chandra Choudhary; Guresh Kumar; Ekta Gupta
Journal:  Virusdisease       Date:  2018-03-21

Review 4.  Direct-acting antiviral agents for HCV infection affecting people who inject drugs.

Authors:  Jason Grebely; Behzad Hajarizadeh; Gregory J Dore
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-08-23       Impact factor: 46.802

5.  A quasi-experimental evaluation of dried blood spot testing through community pharmacies in the Tayside region of Scotland.

Authors:  Andrew Radley; Karen Melville; Jan Tait; Brian Stephens; Josie M M Evans; John F Dillon
Journal:  Frontline Gastroenterol       Date:  2017-01-06

Review 6.  Eligibility of persons who inject drugs for treatment of hepatitis C virus infection.

Authors:  Amber Arain; Geert Robaeys
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

Review 7.  Evidence-based interventions to enhance assessment, treatment, and adherence in the chronic Hepatitis C care continuum.

Authors:  Jaimie P Meyer; Yavar Moghimi; Ruthanne Marcus; Joseph K Lim; Alain H Litwin; Frederick L Altice
Journal:  Int J Drug Policy       Date:  2015-05-17

8.  Ethical issues posed by cluster randomized trials in health research.

Authors:  Charles Weijer; Jeremy M Grimshaw; Monica Taljaard; Ariella Binik; Robert Boruch; Jamie C Brehaut; Allan Donner; Martin P Eccles; Antonio Gallo; Andrew D McRae; Raphael Saginur; Merrick Zwarenstein
Journal:  Trials       Date:  2011-04-20       Impact factor: 2.279

Review 9.  A systematic review of randomized controlled trials of interventions to improve the health of persons during imprisonment and in the year after release.

Authors:  Fiona G Kouyoumdjian; Kathryn E McIsaac; Jessica Liauw; Samantha Green; Fareen Karachiwalla; Winnie Siu; Kaite Burkholder; Ingrid Binswanger; Lori Kiefer; Stuart A Kinner; Mo Korchinski; Flora I Matheson; Pam Young; Stephen W Hwang
Journal:  Am J Public Health       Date:  2015-02-25       Impact factor: 9.308

10.  Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs.

Authors:  Jason Grebely; Julie Bruneau; Jeffrey V Lazarus; Olav Dalgard; Philip Bruggmann; Carla Treloar; Matthew Hickman; Margaret Hellard; Teri Roberts; Levinia Crooks; Håvard Midgard; Sarah Larney; Louisa Degenhardt; Hannu Alho; Jude Byrne; John F Dillon; Jordan J Feld; Graham Foster; David Goldberg; Andrew R Lloyd; Jens Reimer; Geert Robaeys; Marta Torrens; Nat Wright; Icro Maremmani; Brianna L Norton; Alain H Litwin; Gregory J Dore
Journal:  Int J Drug Policy       Date:  2017-07-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.